BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 17973895)

  • 1. New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review.
    Panzer S
    Vox Sang; 2008 Jan; 94(1):1-5. PubMed ID: 17973895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment options for chronic refractory idiopathic thrombocytopenic purpura in adults: focus on romiplostim and eltrombopag.
    Chouhan JD; Herrington JD
    Pharmacotherapy; 2010 Jul; 30(7):666-83. PubMed ID: 20575632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Recent advances in the treatment of idiopathic thrombocytopenic purpura].
    Kurata Y
    Rinsho Ketsueki; 2007 May; 48(5):355-62. PubMed ID: 17571579
    [No Abstract]   [Full Text] [Related]  

  • 4. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management.
    Stasi R; Evangelista ML; Stipa E; Buccisano F; Venditti A; Amadori S
    Thromb Haemost; 2008 Jan; 99(1):4-13. PubMed ID: 18217129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging strategies to treat chronic immune thrombocytopenic purpura.
    Newland A
    Eur J Haematol Suppl; 2008 Feb; (69):27-33. PubMed ID: 18211570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New options after first-line therapy for chronic immune thrombocytopenic purpura.
    Burzynski J
    Am J Health Syst Pharm; 2009 Jan; 66(2 Suppl 2):S11-21. PubMed ID: 19139486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two new drugs for chronic ITP.
    Med Lett Drugs Ther; 2009 Feb; 51(1305):10-1. PubMed ID: 19197233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positioning new treatments in the management of immune thrombocytopenia.
    Arnold DM
    Pediatr Blood Cancer; 2013; 60 Suppl 1(Suppl 1):S19-22. PubMed ID: 23109488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New treatments for idiopathic thrombocytopenic purpura: rethinking old hypotheses.
    Arnold DM; Nazi I; Kelton JG
    Expert Opin Investig Drugs; 2009 Jun; 18(6):805-19. PubMed ID: 19426124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New treatment options for primary immune thrombocytopenia].
    Gudbrandsdottir S; Frederiksen H; Birgens HS; Nielsen CH; Nielsen OJ; Stentoft J; Hasselbalch HC
    Ugeskr Laeger; 2011 Jan; 173(4):271-4. PubMed ID: 21262171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP).
    Boyers D; Jia X; Crowther M; Jenkinson D; Fraser C; Mowatt G
    Health Technol Assess; 2011 May; 15 Suppl 1():23-32. PubMed ID: 21609650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
    Puavilai T; Thadanipon K; Rattanasiri S; Ingsathit A; McEvoy M; Attia J; Thakkinstian A
    Br J Haematol; 2020 Feb; 188(3):450-459. PubMed ID: 31423574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
    Kuter DJ
    Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura.
    Nurden AT; Viallard JF; Nurden P
    Lancet; 2009 May; 373(9674):1562-9. PubMed ID: 19324405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thrombopoietin-receptor agonists: a revolution in the therapeutic strategies of immune thrombocytopenic purpura?].
    Godeau B;
    Rev Med Interne; 2009 Mar; 30(3):203-5. PubMed ID: 19019500
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.
    Bussel JB; Provan D; Shamsi T; Cheng G; Psaila B; Kovaleva L; Salama A; Jenkins JM; Roychowdhury D; Mayer B; Stone N; Arning M
    Lancet; 2009 Feb; 373(9664):641-8. PubMed ID: 19231632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia.
    Tamary H; Roganovic J; Chitlur M; Nugent DJ
    Ann Hematol; 2010 Jul; 89 Suppl 1(Suppl 1):5-10. PubMed ID: 20358200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding and mortality outcomes in ITP clinical trials: a review of thrombopoietin mimetics data.
    Altomare I; Wasser J; Pullarkat V
    Am J Hematol; 2012 Oct; 87(10):984-7. PubMed ID: 22729832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis.
    Yang R; Lin L; Yao H; Ji O; Shen Q
    Hematology; 2019 Dec; 24(1):290-299. PubMed ID: 30661482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New insights and therapeutics for immune-mediated thrombocytopenia.
    Metjian A; Abrams CS
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):71-84. PubMed ID: 18095908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.